Izidakamizwa ezivunyelwe ukwelashwa kohlobo lwesifo sikashukela 2

Amakilasi omuthi amasha ahlinzeka ngokulawula ukulawula i-glycemic

Ukwelapha uhlobo lwesifo sikashukela se-2 kuye kwaguqulwa eminyakeni eyishumi eyedlule ngokusungulwa kwemithi emisha, amakilasi ezidakamizwa, kanye nezinqubo zokwelashwa. Lezi zintuthuko zinikeza abantu abanesifo sikashukela ngohlu olubanzi lwezindlela zokwelapha ezihlangene ezikwazi ukuhlinzeka ngokulawulwa okunamandla kwe-glycemic esikhathini eside.

Imithi evunyelwe idilizwa yiklasi lezidakamizwa, ngalinye elihlinzeka ngezindlela ezahlukene zezenzo.

I-DPP-4 Inhibitors

I-dipeptidyl peptidase-4 (DPP-4) inhibitors isebenza ngokuvimbela i-enzyme ye-DPP-4 ebulala i-hormone incretin. I-Incretins isiza umzimba ukuthi ukhiqize i-insulin engaphezulu uma kudingeka futhi unciphise inani le-glucose elikhiqizwa yisibindi uma kungadingeki. Kukhona okwamanje ama-inhibitors amahlanu e-DPP-4 avunywe yi-US Food and Drug Administration (FDA):

Incretin Mimetics

Njengamagama abo, i-incretin mimetics isebenza ngokulingisa isenzo se-incretins sokukhuthaza ukukhiqizwa kwe- insulini . Zibuye zinciphise izinga lokugaya ukuze i-glucose ingene egazini kancane kancane.

Kunezinhlobo ezinhlanu ze-incretin mimetics okwamanje ezivunyiwe yi-FDA ezithunyelwa ngomjovo futhi zisetshenziswe kubantu abangakwazi ukulawula ushukela wegazi ngemithi yomlomo:

Eyaziwa nangokuthi i -agonists ye-GLP-1 ye-receptor , izidakamizwa zisetshenziselwa ukuhlanganiswa nemithi yomlomo futhi ziza emakhosini we-injector asetshenzisiwe. Azizona insulin noma zisetshenziswe esikhundleni se-insulini.

I-Sodium-Glucose Transporter-2 Inhibitors ekhethiwe

I-sodium-glucose transporter-2 (SSGT-2) inhibitors ekhethiwe iyakwazi ukwehlisa ushukela wegazi ngokubangela izinso ukususa iglucose emzimbeni ngokusebenzisa umchamo.

Kunezinketho ezintathu zezidakamizwa ezivunyelwe i-FDA:

Ama-analog anama-Amylin

Ama-analogs ase-Amylin yizinguqulo ezifakwe ngamanoni we-hormone amylin asetshenziselwa ama-pancreas ukunciphisa amazinga kashukela egazini. Ama-analogs a-Amylin abuye ahanjiswe ngomjovo futhi asetshenziselwe eceleni kwe-insulin yokulawula ukulawula igazi kwegazi. Okwamanje ukhetho olulodwa oluvunyelwe i-FDA:

Sulfonylureas

Sulfonylureas yiwona omdala kakhulu omlomo wesifo sikashukela futhi, kuze kube ngu-1995, okuwukuphela kwezinto ezitholakalayo zokuphatha uhlobo lwesifo sikashukela sohlobo lwe-2. I-Sulfonylureas isebenza ngokuvuselela ama-pancreas ukukhulula i-insulin engena egazini.

Kunezizukulwane eziningana ze-sulfonylureas; okwesibili nesithathu yizona ezivame ukushiwo. Kulabo okwamanje abavunyelwe yi-FDA:

Biguanides

Ama-Biguanides anciphisa inani le- glucose elikhiqizwa yisibindi ngesikhathi lenza umzimba uzwele kakhulu kwi-insulin. Kunezinhlobo ezimbili ezigunyaziwe ze-FDA zomuthi ofanayo:

I-Alpha-Glucosidase Inhibitors

Ama-inhibitors e-Alpha-glucosidase aphuza ukuguqulwa kwama-carbohydrate kuya kweglucose ngesikhathi sokugaya. Lokhu kusiza ukulawula amazinga we-glucose wegazi futhi kuvimbele ushukela ekukhuphukeni kakhulu. Kunezinketho ezimbili ezivunyelwe yi-FDA:

Thiazolidinediones

I-Thiazolidinediones ivuselela amangqamuzana omzimba namafutha ukuze amukele kalula i-insulini. Zombili zifaka izingozi ezithile zempilo ezidinga ukubonisana ngokukhethekile ngaphambi kokuqala ukwelashwa. I-FDA ivume izidakamizwa ezimbili ze-thiazolidinedione e-US:

Ngo-May 2007, i-FDA ikhishwe isaziso sokuphepha mayelana nobungozi bokuhlaselwa kwenhliziyo nezinye izenzakalo zenhliziyo lapho uthatha u-Avandia. Ukukhathazeka okufanayo kwaholela ekuvinjelweni kokubili u-Avandia no-Actos eFrance naseJalimane.

I-Meglitinides

I-Meglitinides ingasiza ekuvuseleleni ukukhiqizwa kwe-insulin uma kune-glucose egazini. Uma ushukela wegazi uphansi, umuthi awuphumelelanga kakhulu. Izinketho ezivunyelwe i-FDA zifaka:

> Umthombo:

> Ukuphathwa Kwezokudla Nezidakamizwa zase-US. "Imithi Ye-Diabetes Evunyelwe I-FDA." I-Silver Spring, e-Maryland.